Product
Cobimetinib
Aliases
Cotellic, Cotellic®, COTELLIC, GDC-0973 (3 other aliases)
Name
Cotellic
INN Name
COBIMETINIB
FDA Approved
Yes
57 clinical trials
1 organization
143 indications
1 document
Indication
MelanomaIndication
Colorectal CancerIndication
Colon CancerIndication
Advanced or Metastatic Solid TumorsIndication
Metastatic MelanomaIndication
Advanced Solid TumorIndication
BRAF V600 MutationIndication
CancerIndication
Solid TumorsIndication
Bile Duct CancerIndication
Salivary CancerIndication
Bladder CancerIndication
Lung CancerIndication
Pancreatic adenocarcinomaIndication
Gastric AdenocarcinomaIndication
Ovarian CancerIndication
Multiple MyelomaIndication
Solid TumorIndication
Breast CancerIndication
Cancer of Unknown Primary SiteIndication
Ovarian cancerIndication
Skin CancerIndication
Breast CarcinomaIndication
Malignant NeoplasmIndication
Pancreatic CarcinomaIndication
Prostate CancerIndication
Advanced SarcomaIndication
Breast Cancer, Stage IVIndication
Soft Tissue SarcomaIndication
Recurrent Ovarian CarcinomaIndication
Pancreatic CancerIndication
Stage III Ovarian Cancer AJCC v8Indication
Stage III Pancreatic CancerIndication
Stage IV Ovarian CancerIndication
Gallbladder CancerIndication
CholangiocarcinomaIndication
Intrahepatic CholangiocarcinomaIndication
Gastrointestinal CancerIndication
Stage IIA Pancreatic Cancer AJCC v8Indication
Stage IIB Pancreatic Cancer AJCC v8Indication
Recurrent Acute Myeloid LeukemiaIndication
Acute Myeloid LeukemiaIndication
Metastatic Lung Non-Small Cell CarcinomaIndication
Recurrent Lung Non-Small Cell CarcinomaIndication
Refractory Non-Small Cell Lung CarcinomaIndication
Stage IV Lung CancerIndication
Endometrial CancerIndication
Endometrial CarcinomaIndication
Fallopian Tube CarcinomaIndication
Platinum-Resistant Ovarian CarcinomaIndication
Primary Peritoneal CarcinomaIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Uterine Corpus Cancer (Stage III)Indication
Stage IV Uterine Corpus Cancer AJCC v8Indication
Squamous Cell CarcinomaIndication
Appendiceal AdenocarcinomaIndication
Rare LesionIndication
Locally Advanced Malignant NeoplasmIndication
Skin Squamous Cell CarcinomaIndication
Metastatic Malignant NeoplasmIndication
Small Intestinal AdenocarcinomaIndication
Neoplastic SyndromeIndication
Small Intestinal Adenocarcinoma AJCC v8Indication
Histiocytic DisordersIndication
Advanced CancerIndication
Haematological MalignancyIndication
Langerhans Cell HistiocytosisIndication
Juvenile XanthogranulomaIndication
Erdheim-Chester DiseaseIndication
Neurodegenerative DiseaseIndication
Histiocytic SarcomaIndication
malignantIndication
Cutaneous MelanomaIndication
Stage IIIC Cutaneous Melanoma AJCC v8Indication
Stage IIID Cutaneous Melanoma AJCC v8Indication
Inflammatory Breast CarcinomaIndication
Breast Inflammatory CarcinomaIndication
Thyroid CancerIndication
PapillaryIndication
Laryngeal NeoplasmsIndication
cancerIndication
Non-Small Cell LungIndication
GliomaIndication
AnaplasticIndication
Fallopian tube cancerIndication
BCR-ABL1-positiveIndication
AnaemiaIndication
Hodgkin lymphomaIndication
Non-Hodgkin LymphomaIndication
Hodgkin Lymphoma, Ann Arbor Stage IVIndication
Stage IV Non-Hodgkin LymphomaIndication
Atypical chronic myeloid leukemiaIndication
BCR-ABL1 NegativeIndication
Blast Phase Chronic Myelogenous LeukemiaIndication
Castration-Resistant Prostate CarcinomaIndication
Chronic Myelogenous LeukemiaIndication
Metastatic Malignant Solid NeoplasmIndication
UnclassifiableIndication
Primary MyelofibrosisIndication
Acute Lymphoblastic LeukemiaIndication
Chronic Lymphocytic LeukemiaIndication
Recurrent Hematologic MalignancyIndication
Hodgkin LymphomaIndication
Myelodysplastic SyndromeIndication
Myeloproliferative NeoplasmIndication
Small Lymphocytic LymphomaIndication
Refractory Chronic Lymphocytic LeukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
Refractory Hematologic MalignancyIndication
Hodgkin's LymphomaIndication
Malignant Solid NeoplasmIndication
Refractory Non-Hodgkin LymphomaIndication
MyelofibrosisIndication
Pancreatic AdenocarcinomaIndication
Malignant Melanoma Stage IVIndication
Brain MetastasesIndication
BRAF V600E Mutation PresentIndication
Papillary CraniopharyngiomaIndication
Metastatic Thyroid CancerIndication
Thyroid CarcinomaIndication
Anaplastic Thyroid CarcinomaIndication
BRAF V600 Wild TypeIndication
Stage IV Cutaneous MelanomaIndication
Gallbladder CarcinomaIndication
Stage IV Distal Bile Duct Cancer AJCC v8Indication
Liver CancerIndication
NSCLCClinical trial
A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon CancerStatus: Active (not recruiting), Estimated PCD: 2024-02-16
Clinical trial
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2019-02-05
Clinical trial
A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2019-10-11
Clinical trial
A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF MutationsStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These AgentsStatus: Completed, Estimated PCD: 2023-05-24
Clinical trial
NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)Status: Active (not recruiting), Estimated PCD: 2025-10-31
Clinical trial
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)Status: Recruiting, Estimated PCD: 2028-07-05
Clinical trial
Comparative Effectiveness of Different Targeted Therapies for BRAF-mutated Unresectable/Metastatic Melanoma in the United StatesStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)Status: Active (not recruiting), Estimated PCD: 2024-08-24
Clinical trial
A Phase II Two Cohort Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System MetastasesStatus: Completed, Estimated PCD: 2021-06-07
Clinical trial
A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 TherapyStatus: Active (not recruiting), Estimated PCD: 2025-11-28
Clinical trial
A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsStatus: Active (not recruiting), Estimated PCD: 2028-05-30
Clinical trial
A Phase Ib/II Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Patients With Relapsed and Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2021-05-18
Clinical trial
A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib In Pediatric and Young Adult Patients With Previously Treated Solid TumorsStatus: Completed, Estimated PCD: 2021-07-21
Clinical trial
Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLCStatus: Completed, Estimated PCD: 2022-02-08
Clinical trial
A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type MelanomaStatus: Terminated, Estimated PCD: 2019-04-15
Clinical trial
A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast CancerStatus: Terminated, Estimated PCD: 2018-08-10
Clinical trial
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2023-02-14
Clinical trial
A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian CancerStatus: Completed, Estimated PCD: 2023-07-12
Clinical trial
Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV MelanomaStatus: Active (not recruiting), Estimated PCD: 2019-10-31
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)Status: Withdrawn, Estimated PCD: 2026-05-31
Clinical trial
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable CholangiocarcinomaStatus: Completed, Estimated PCD: 2020-08-07
Clinical trial
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase I, Open-Label, Dose Finding Study of Calaspargase Pegol-Mnkl in Combination With Cobimetinib in Locally-Advanced or Metastatic Pancreatic CancerStatus: Recruiting, Estimated PCD: 2024-12-16
Clinical trial
Phase 1b Study of IDH Inhibition With Enasidenib and MEK Inhibition With Cobimetinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene MutationsStatus: Recruiting, Estimated PCD: 2025-05-02
Clinical trial
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-17
Clinical trial
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
"NEOadjuvant Plus Adjuvant Therapy With Combination or Sequence of Vemurafenib, cobImetinib, and atezolizuMab in Patients With High-risk, Surgically Resectable BRAF Mutated and Wild-type Melanoma"Status: Active (not recruiting), Estimated PCD: 2023-12-15
Clinical trial
A Phase II, Open-Label, Single-Arm, Multi-Cohort, Proof-of-Principle Study to Investigate the Efficacy of Cobimetinib and Atezolizumab in Advanced Rare TumorsStatus: Completed, Estimated PCD: 2024-04-02
Clinical trial
MEGALiT - a Multicenter, Basket and Umbrella Explorative Trial on the Efficacy and Safety of Molecular Profile Selected Commercially Available Targeted Anti-cancer Drugs in Patients With Advanced Cancers Progressive on Standard TherapyStatus: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
Phase II Trial of Single-agent Cobimetinib for Adults With Histiocytic DisordersStatus: Completed, Estimated PCD: 2022-12-16
Clinical trial
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLCStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular ProfileStatus: Recruiting, Estimated PCD: 2026-11-25
Clinical trial
A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 2 Trial of Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway MutationsStatus: Recruiting, Estimated PCD: 2025-08-15
Clinical trial
Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical TrialStatus: Recruiting, Estimated PCD: 2025-06-29
Clinical trial
Cobimetinib for BRAF-wild-type or Mutated Histiocytoses : a Randomized, Placebo-controlled, Double Blind Study" COBRAH StudyStatus: Completed, Estimated PCD: 2021-10-05
Clinical trial
A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) or Atezolizumab + Eribulin (AE) in Patients With Recurrent/Metastatic Inflammatory Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)Status: Recruiting, Estimated PCD: 2028-08-03
Clinical trial
A Multicentre, Open-label, Phase I-II Study Evaluating the Combination of a MEK Inhibitor and a PDL1 Inhibitor in Pediatric and Adult Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma.Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Patients With Recurrent Platinum Resistant High Grade Serous Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-02-28
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIMEStatus: Terminated, Estimated PCD: 2020-12-10
Clinical trial
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaStatus: Completed, Estimated PCD: 2024-03-01
Clinical trial
Phase 1/2 Open-label Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
An Open-label Phase II Multicenter Study of Vemurafenib (Zelboraf®) Plus Cobimetinib (Cotellic®) After Radiosurgery in Patients With Active BRAF-V600-mutant Melanoma Brain MetastasesStatus: Terminated, Estimated PCD: 2023-02-10
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)Status: Active (not recruiting), Estimated PCD: 2025-09-30
Clinical trial
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyStatus: Terminated, Estimated PCD: 2022-12-30
Clinical trial
Phase II Trial of BRAF/MEK Inhibitors in Papillary CraniopharyngiomasStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
COBI-AVM Study - Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib In Extracranial Arteriovenous Malformations (AVM)Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid CarcinomasStatus: Active (not recruiting), Estimated PCD: 2025-07-31
Clinical trial
Phase II Study of BEvacizumab (Avastin) in Combination With Atezolizumab or Atezolizumab (Tencentriq) and Cobimetinib (Cotellic) in Patients With Untreated Melanoma Brain Metastases (TACo-BEAT-MBM)Status: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract CancersStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Continuous ReAssessment With Flexible ExTension in Rare Malignancies - CRAFT: The NCT-PMO-1602 Phase II TrialStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase II Study Investigating Preoperative Combination Strategies for Immunotherapy in Patients With Untreated, Operable ER+, HER2-negative Primary Breast CancerStatus: Completed, Estimated PCD: 2023-08-18
Document
DailyMed Label: CotellicOrganization
Genentech, Inc.